

30
20
10
0
Myocardial Fibrosis (% surface area)
p<0.025
p<0.0005
p<0.0005
Control
VIP(6-16)
VIP(4-16)

Figure 1:



30
20
10
0
Myocardial Fibrosis (% surface area)
p<0.0005
p<0.0005
Zero Time
Control
VIP(6-16)

Figure 2:



30
20
10
0
Myocardial Fibrosis (% surface area)
p<0.0005
p<0.0005
p<0.01
p<0.01
Control
VIP(6-16)
VIP (10-28)
VIP (16-28)
VIP (4-16)
VIP(1-12)

Figure 3



30
20
10
0
Myocardial Fibrosis (% surface area)
p<0.0005
p<0.0005
p<0.0005
Control
Treated (VIP)
Treated (VIP 6-28)
Treated (VIP 6-16)

Figure 4





p<0.05
p<0.025
p<0.005
p<0.01
p<0.0005
p<0.0005
p<0.05
p<0.025
p<0.0005
p<0.0005
Myocardial Fibrosis (% surface area)
40
30
20
10
0
Control
VIP
VIP(6-28)
VIP (10-28)
VIP (16-28)
VIP (4-16)
VIP (1-12)

Figure 5




Systolic blood pressure (SBP) in SHR on 2.2% salt diet after 4 weeks treatment. Peptides were infused at 5pmol/kg/min. * $p<0.05$, ** $p<0.01$, *** $p<0.001$

Figure 6




Systolic blood pressure (SBP) in SHR on 2.2% salt diet after 4 weeks treatment. Peptides were infused at 5pmol/kg/min. * $p<0.01$, ** $p<0.0005$

Figure 7



Systolic blood pressure after 4 weeks treatment in SHR on 2.2% salt diet. Peptides were infused at 5 pmol/kg/min.

Figure 8



Systolic blood pressure (SBP) after 4 weeks treatment in SHR on 2.2% salt diet. Peptides were infused at 5pmol/kg/min

Figure 9